Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia

Nephrology Dialysis Transplantation

Volumn 22, Issue 3, 2007, Pages 712-714

  López Novoa, José M ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Endoglin; Hereditary haemorrhagic telangiectasia; Pre eclampsia; Pregnancy

Indexed keywords

CYCLOOXYGENASE 2; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1;

ACCURACY; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOTHELIUM LESION; HUMAN; KIDNEY DISEASE; MATERNAL HYPERTENSION; NONHUMAN; PATHOGENESIS; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SOLUBILITY; VASODILATATION;

ANIMALS; ANTIGENS, CD; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; PHENOTYPE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROGNOSIS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33847674858     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl768     Document Type: Article

References (16)

1. Sibai BM, Caritis S, Hauth J. What we have learned about preeclampsia. Semin Perinatol 2003; 27: 239-246
2. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
3. Fonsatti E, Maio M. Highlights on endoglin (CD105): From basic findings towards clinical applications in human cancer. J Transl Med 2004; 2: 18 (http://www.translational-medicine.com/content/2/1/18)
4. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002; 277: 29197-29209
5. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104: 1343-1351
6. Torsney E, Charlton R, Diamond AG et al. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 2003; 107: 1653-1657
7. Jerkic M, Rivas-Elena JV, Prieto M et al. Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J 2004; 18: 609-611
8. Jerkic M, Rivas-Elena JV, Santibanez JF et al. Endoglin regulates cyclooxygenase-2 expression and activity. Circ Res 2006; 99: 248-526
9. Toporsian M, Gros R, Kabir MG et al. Role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96: 684-692
10. Jerkic M, Rodriguez-Barbero A, Prieto M et al. Reduced angiogenic responses in adult endoglin beterozygous mice. Cardiovasc Res 2006; 69: 845-854
11. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649
12. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21: 3052-3054
13. Perez-Gomez E, Eleno N, Lopez-Novoa JM et al. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005; 24: 4450-4461
14. Kaufmann P, Castellucci M. Extravillous trophoblast in the human placenta. A review. Trophoblast Res 1997; 10: 21-65
15. Davison JM, Homuth V, Jeyabalan A et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004; 15: 2440-2448
16. Santibanez JF, Letamendia A, Perez-Barriocanal F et al. Endoglin increases eNOS expression by modulating smad2 protein levels and smad2-dependent TGF-β signaling. J Cell Physiol 2007; 210: 456-468